Xia C, Dong X, Li H, Cao M, Sun D, He S, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J (Engl). 2022;135:584–90. https://doi.org/10.1097/CM9.0000000000002108.

Article  PubMed  PubMed Central  Google Scholar 

Zhu L, Wang T, Wu J, Zhai X, Wu Q, Deng H, et al. Updated interpretation of the NCCN clinical practice guidelines (Version 3. 2023) for non-small cell lung cancer. Chin J Lung Cancer. 2023;26:407–15. https://doi.org/10.3779/j.issn.1009-3419.2023.102.18.

Article  CAS  Google Scholar 

Dong ZY, Zhong WZ, Zhang XC, Su J, Xie Z, Liu SY, et al. Potential predictive value of TP53 and KRAS mutation status for response to PD-1 blockade immunotherapy in lung adenocarcinoma. Clin Cancer Res. 2017;23:3012–24. https://doi.org/10.1158/1078-0432.CCR-16-2554.

Article  CAS  PubMed  Google Scholar 

Hsu PC, Jablons DM, Yang CT, You L. Epidermal growth factor receptor (EGFR) pathway, yes-associated protein (YAP) and the regulation of programmed death-ligand 1 (PD-L1) in non-small cell lung cancer (NSCLC). Int J Mol Sci. 2019;20(15):3821. https://doi.org/10.3390/ijms20153821.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu SY, Dong S, Yang XN, Liao RQ, Jiang BY, Wang Q, et al. Neoadjuvant nivolumab with or without platinum-doublet chemotherapy based on PD-L1 expression in resectable NSCLC (CTONG1804): a multicenter open-label phase II study. Signal Transduct Target Ther. 2023;8(1):442. https://doi.org/10.1038/s41392-023-01700-4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lee CK, Man J, Lord S, Cooper W, Links M, Gebski V, et al. Clinical and molecular characteristics associated with survival among patients treated with checkpoint inhibitors for advanced non-small cell lung carcinoma: a systematic review and meta-analysis. JAMA Oncol. 2018;4:210–6. https://doi.org/10.1001/jamaoncol.2017.4427.

Article  PubMed  PubMed Central  Google Scholar 

Ilie M, Long-Mira E, Bence C, Butori C, Lassalle S, Bouhlel L, et al. Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies. Ann Oncol. 2016;27:147–53. https://doi.org/10.1093/annonc/mdv489.

Article  CAS  PubMed  Google Scholar 

Huang N, Sun X, Li P, Liu X, Zhang X, Chen Q, et al. TRIM family contribute to tumorigenesis, cancer development, and drug resistance. Exp Hematol Oncol. 2022;11:75. https://doi.org/10.1186/s40164-022-00322-w.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mohapatra B, Lavudi K, Kokkanti RR, Patnaik S. Regulation of NLRP3/TRIM family signaling in gut inflammation and colorectal cancer. Biochim Biophys Acta Rev Cancer. 2025;1880:189271. https://doi.org/10.1016/j.bbcan.2025.189271.

Article  CAS  PubMed  Google Scholar 

Wei CH, Weng CW, Wu CY, Chen HY, Chang YH, Chang GC, et al. E3 ligase TRIM8 suppresses lung cancer metastasis by targeting MYOF degradation through K48-linked polyubiquitination. Cell Death Dis. 2025;16:88. https://doi.org/10.1038/s41419-025-07421-6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bai X, Tang J. TRIM proteins in breast cancer: Function and mechanism. Biochem Biophys Res Commun. 2023;640:26–31. https://doi.org/10.1016/j.bbrc.2022.11.103.

Article  CAS  PubMed  Google Scholar 

Lu K, Pan Y, Huang Z, Liang H, Ding ZY, Zhang B. TRIM proteins in hepatocellular carcinoma. J Biomed Sci. 2022;29:69. https://doi.org/10.1186/s12929-022-00854-7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jiang T, Xia Y, Li Y, Lu C, Lin J, Shen Y, et al. TRIM29 promotes antitumor immunity through enhancing IGF2BP1 ubiquitination and subsequent PD-L1 downregulation in gastric cancer. Cancer Lett. 2024;581:216510. https://doi.org/10.1016/j.canlet.2023.216510.

Article  CAS  PubMed  Google Scholar 

Huang XQ, Zhang XF, Xia JH, Chao J, Pan QZ, Zhao JJ, et al. Tripartite motif-containing 3 (TRIM3) inhibits tumor growth and metastasis of liver cancer. Chin J Cancer. 2017;36:77. https://doi.org/10.1186/s40880-017-0240-5.

Article  PubMed  PubMed Central  Google Scholar 

Fu H, Yang H, Zhang X, Wang B, Mao J, Li X, et al. Exosomal TRIM3 is a novel marker and therapy target for gastric cancer. J Exp Clin Cancer Res. 2018;37:162. https://doi.org/10.1186/s13046-018-0825-0.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Song Y, Guo Q, Gao S, Hua K. Tripartite motif-containing protein 3 plays a role of tumor inhibitor in cervical cancer. Biochem Biophys Res Commun. 2018;498:686–92. https://doi.org/10.1016/j.bbrc.2018.03.046.

Article  CAS  PubMed  Google Scholar 

Chen G, Kong J, Tucker-Burden C, Anand M, Rong Y, Rahman F, et al. Human Brat ortholog TRIM3 is a tumor suppressor that regulates asymmetric cell division in glioblastoma. Cancer Res. 2014;74:4536–48. https://doi.org/10.1158/0008-5472.CAN-13-3703.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Piao MY, Cao HL, He NN, Xu MQ, Dong WX, Wang WQ, et al. Potential role of TRIM3 as a novel tumour suppressor in colorectal cancer (CRC) development. Scand J Gastroenterol. 2016;51:572–82. https://doi.org/10.3109/00365521.2015.1124285.

Article  CAS  PubMed  Google Scholar 

Zhu J, Wu G, Ke Z, Cao L, Tang M, Li Z, et al. Targeting TRIM3 deletion-induced tumor-associated lymphangiogenesis prohibits lymphatic metastasis in esophageal squamous cell carcinoma. Oncogene. 2019;38:2736–49. https://doi.org/10.1038/s41388-018-0621-5.

Article  CAS  PubMed  Google Scholar 

Chao J, Zhang XF, Pan QZ, Zhao JJ, Jiang SS, Wang Y, et al. Decreased expression of TRIM3 is associated with poor prognosis in patients with primary hepatocellular carcinoma. Med Oncol. 2014;31:102. https://doi.org/10.1007/s12032-014-0102-9.

Article  CAS  PubMed  Google Scholar 

Li Y, Zhang Y, Cao G, Zheng X, Sun C, Wei H, et al. Blockade of checkpoint receptor PVRIG unleashes anti-tumor immunity of NK cells in murine and human solid tumors. J Hematol Oncol. 2021;14:100. https://doi.org/10.1186/s13045-021-01112-3.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Thol K, Pawlik P, McGranahan N. Therapy sculpts the complex interplay between cancer and the immune system during tumour evolution. Genome Med. 2022;14:137. https://doi.org/10.1186/s13073-022-01138-3.

Article  PubMed  PubMed Central  Google Scholar 

Guo J, Yang L, Li X, Rao X, Chen F, Wu P, et al. The role of EGFR mutations in sensitivity of PD-1/PD-L1 blockade in non-small cell lung cancer. Am J Cancer Res. 2025;15:5105–18. https://doi.org/10.62347/OZKE5561.

Article  PubMed  PubMed Central  Google Scholar 

Hu Y, Lu Y, Xing F, Hsu W. FGFR1/MAPK-directed brachyury activation drives PD-L1-mediated immune evasion to promote lung cancer progression. Cancer Lett. 2022;547:215867. https://doi.org/10.1016/j.canlet.2022.215867.

Article  CAS  PubMed  Google Scholar 

Gong B, Kiyotani K, Sakata S, Nagano S, Kumehara S, Baba S, et al. Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer. J Exp Med. 2019;216:982–1000. https://doi.org/10.1084/jem.20180870.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Qiu Z, Song N, Li A, Singh D, Prasad CB, Yan C, et al. PPP2R2A insufficiency enhances PD-L1 immune checkpoint blockade efficacy in lung cancer through cGAS-STING activation. J Clin Invest. 2025;136(4):e193354. https://doi.org/10.1172/JCI193354.

Article  PubMed  PubMed Central